Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

NCT: NCT03601702 · RECRUITING

NCT IDNCT03601702
StatusRECRUITING
Start Date2022-01-01
Completion2027-06-15

Brief Summary

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

Frequently Asked Questions

What is EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke?

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke is a clinical trial registered under NCT03601702. Current status: RECRUITING.

What is the status of NCT03601702?

The current status of NCT03601702 (EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke) is: RECRUITING.

When did EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke start?

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke started on 2022-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑